In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $22.5 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $22.21, down -1.29%. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 1.75 million shares were traded. ACAD stock price reached its highest trading level at $23.09 during the session, while it also had its lowest trading level at $22.18.
Ratios:
Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.04. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 04 ’25 when Brege Laura sold 14,446 shares for $21.78 per share. The transaction valued at 314,634 led to the insider holds 15,095 shares of the business.
LAURA BREGE bought 14,446 shares of ACAD for $314,638 on Jun 04 ’25. On May 16 ’25, another insider, Kihara James, who serves as the PRINCIPAL ACCOUNTING OFFICER of the company, sold 4,000 shares for $22.50 each. As a result, the insider received 90,000 and left with 20,395 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3717109760 and an Enterprise Value of 3091535616. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.17, and their Forward P/E ratio for the next fiscal year is 26.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.73 while its Price-to-Book (P/B) ratio in mrq is 4.85. Its current Enterprise Value per Revenue stands at 3.103 whereas that against EBITDA is 30.409.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.65, which has changed by 0.3667692 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $25.23, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 16.03%, while the 200-Day Moving Average is calculated to be 27.39%.
Shares Statistics:
The stock has traded on average 2.14M shares per day over the past 3-months and 2127360 shares per day over the last 10 days, according to various share statistics. A total of 167.12M shares are outstanding, with a floating share count of 166.02M. Insiders hold about 0.80% of the company’s shares, while institutions hold 103.73% stake in the company. Shares short for ACAD as of 1749772800 were 15435884 with a Short Ratio of 7.20, compared to 1747267200 on 15243471. Therefore, it implies a Short% of Shares Outstanding of 15435884 and a Short% of Float of 14.530000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
